Ranbaxy Laboratories - the country's largest drug maker -has gained final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market and manufacture Topirimate tablets 25mg, l0Omg & 200mg for treating seizures.
The application for the drug was submitted by Ranbaxy from the Ohm Laboratories manufacturing facility, located in North Brunswick, New Jersey, USA. Ohm, based in North Brunswick, New Jersey, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Ohm is engaged in the sale and distribution of generic and branded private label, OTC products in the US healthcare system.
Content Guide
